Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs
Authors:
- Aida N. KawumaAKAida N. Kawuma
- Francis Williams OjaraFOFrancis Williams Ojara
- Allan BuzibyeABAllan Buzibye
- Barbara CastelnuovoBCBarbara Castelnuovo
- Jovia C. TabwendaJTJovia C. Tabwenda
- Jacqueline KyeyuneJKJacqueline Kyeyune
- Christine TuryahabweCTChristine Turyahabwe
- Simon Peter AsiimweSASimon Peter Asiimwe
- Johnson MagoolaJMJohnson Magoola
- Lubbe WiesnerLWLubbe Wiesner
- Ritah NakijobaRNRitah Nakijoba
- Catriona WaittCWCatriona Waitt
Open Access
- 2 October 2024
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (11) , 1915-1923
Abstract
Pharmacokinetic studies are important for understanding drug disposition in the human body. However, pregnant and lactating women are often excluded from primary pharmacokinetic studies and as such there is often limited dosing information regarding drug use in pregnant and/or lactating women. The objectives of this interim analysis were to define the transfer of rifampicin to a breastfed infant and to determine the area under the concentration–time curve of rifampicin in maternal plasma, breastmilk and infant plasma. Performing this interim analysis enabled us to substantiate whether prior assumptions we made on several study design issues including patient sample size and pharmacokinetic sampling times held and whether we needed to amend our protocol or not. We enrolled lactating mothers on treatment for tuberculosis with their breastfeeding infants (below 12 months of age), performed intensive pharmacokinetic sampling (0–24 h post‐dose) on plasma samples from both the mother, infant(s) and breastmilk samples from the mother on two separate occasions (once during the initiation phase and another during the continuation phase of tuberculosis treatment). The initial study design, including sampling times, was informed by a stochastic simulation and estimation exercise, with very limited prior breastmilk data. An interim analysis after recruiting 6 mother–infant pairs ascertained that our initial assumptions were ideal for achieving our study objectives and no amendments to the sampling times were necessary. Initial data from 6 mother–infant pairs show that rifampicin penetrates breastmilk with an approximate milk‐to‐plasma ratio of 0.169 and 0.189 on two separate visits. However, it was undetectable in most infants.Keywords
Funding Information
- Wellcome Trust (222075_Z_20_Z)
- National Institutes of Health (UM1 AI068634, UM1 AI068636, UM1 AI106701)
- National Institute of Allergy and Infectious Diseases (U01 AI068632)
- National Institute of Mental Health (AI068632)
This publication has 16 references indexed in Scilit:
- Attaining Equity of Access to Research: Perspective on Research in Pregnancy and Breastfeeding Following Dolores Shockley Lecture at ASCPT2024Clinical Pharmacology & Therapeutics, 2024
- Concentrations of rifampicin in pre-dose samples in patients with pulmonary tuberculosisThe Brazilian Journal of Infectious Diseases, 2019
- Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human TuberculosisClinical Pharmacokinetics, 2019
- Population Pharmacokinetics of Rifampin in Pregnant Women with Tuberculosis and HIV Coinfection in Soweto, South AfricaAntimicrobial Agents and Chemotherapy, 2016
- Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionAntimicrobial Agents and Chemotherapy, 2016
- Tuberculosis in pregnancy: an estimate of the global burden of diseaseThe Lancet Global Health, 2014
- Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and XposeCPT: Pharmacometrics & Systems Pharmacology, 2013
- Statistics in Medicine — Reporting of Subgroup Analyses in Clinical TrialsNew England Journal of Medicine, 2007
- Drug excretion into breast milk—OverviewAdvanced Drug Delivery Reviews, 2003
- Monitoring of clinical trials: Issues and recommendationsControlled Clinical Trials, 1993